Pipeline (3036)
| Drug | Company | Phase | Trials | Target | MOA | Src |
|---|---|---|---|---|---|---|
| PFE-3703 | Phase 1/2 | 2 | CDK2 | Trial | ||
| PFE-5501 | Phase 1 | 2 | BTK | Trial | ||
| PFE-8662 | NDA/BLA | 1 | CD19 | Trial | ||
| PFE-2901 | Phase 2 | 2 | AHR | Trial | ||
| PFE-7550 | Phase 3 | 3 | Aβ | Trial | ||
| PFE-1944 | NDA/BLA | 1 | APOC3 | Trial | ||
| PFE-1085 | Preclinical | 1 | FXIa | Trial | ||
| PFE-2191 | NDA/BLA | 1 | GLP-1R | Trial | ||
| PFE-7809 | Phase 1 | 1 | DLL3 | Trial | ||
| PFE-5767 | Phase 1/2 | 2 | BET | Trial | ||
| Terafutibatinib | Phase 1/2 | 2 | CD38 | Trial | ||
| Miriosocimab | Phase 1 | 2 | PARP | Trial | ||
| Sotovorutinib | Approved | 1 | Aβ | Trial | ||
| Voxacilimab | Phase 2 | 2 | TYK2 | Trial | ||
| Zanuderotide | Phase 2/3 | 2 | TIGIT | Trial | ||
| JNJ-179 | Approved | 4 | KRASG12C | Trial | ||
| JNJ-8168 | Phase 2/3 | 1 | FLT3 | Trial | ||
| Niranesiran | Phase 2 | 1 | KIF18A | Trial | ||
| Voxaderotide | NDA/BLA | 1 | PI3Kα | Trial | ||
| Mavutenlimab | Phase 3 | 2 | Cl18.2 | Trial | ||
| JNJ-2735 | Phase 2/3 | 2 | Cl18.2 | Trial | ||
| JNJ-5094 | Phase 2/3 | 2 | GIP-R | Trial | ||
| JNJ-8637 | NDA/BLA | 1 | CD20 | Trial | ||
| JNJ-7458 | Phase 1/2 | 1 | PD-1 | Trial | ||
| Nirarelsin | Phase 2 | 2 | PRMT5 | Trial | ||
| Cevizanubrutinib | Preclinical | 1 | FcRn | Trial | ||
| Riboinavolisib | Phase 2/3 | 2 | GLP-1R | Trial | ||
| JNJ-8232 | NDA/BLA | 1 | MALT1 | Trial | ||
| Tirzepatide | Approved | 4 | GLP-1R | Co | ||
| LLY-6079 | Phase 2 | 2 | MDM2 | Trial | ||
| LLY-9749 | Phase 3 | 2 | C5 | Trial | ||
| Nidasacituzumab | Approved | 3 | CFTR | Trial | ||
| Ivorelsin | Approved | 1 | JAK1 | Trial | ||
| LLY-1956 | Phase 1/2 | 1 | BCMA | Trial | ||
| LLY-8369 | Approved | 3 | Menin | Trial | ||
| LLY-1184 | NDA/BLA | 1 | C5 | Trial | ||
| LLY-8903 | Preclinical | 1 | CD47 | Trial | ||
| LLY-4358 | Phase 3 | 4 | B7-H3 | Trial | ||
| LLY-1592 | NDA/BLA | 2 | FGFR | Trial | ||
| LLY-3251 | Phase 2 | 2 | MDM2 | Trial | ||
| Doxacapivasertib | Phase 3 | 1 | APOC3 | Trial | ||
| Lisonaritide | Phase 3 | 4 | IL-13 | Trial | ||
| RHH-1969 | Approved | 1 | BET | Trial | ||
| RHH-974 | Preclinical | 1 | JAK1 | Trial | ||
| RHH-8550 | Approved | 3 | BCL-2 | Trial | ||
| RHH-7558 | Phase 1 | 1 | SGLT2 | Trial | ||
| RHH-5389 | Preclinical | 1 | RET | Trial | ||
| RHH-682 | Phase 2 | 2 | FXIa | Trial | ||
| RHH-1546 | Phase 2/3 | 1 | C5 | Trial | ||
| RHH-7975 | Phase 3 | 1 | FXIa | Trial |